Hvis patienten bliver gravid eller planlægger at blive gravid under behandlingen med Rebif, skal hun informeres om den potentielle risiko, og ophør af behandlingen bør overvejes (se pkt.
If the patient becomes pregnant or plans to become pregnant while taking Rebif she should be informed of the potential hazards and discontinuation of therapy should be considered (see section 5.3).